What question did this study set out to answer?

This research aims to evaluate the antitumor activity of the PARP inhibitor AG014699 in human cancer cells with mutations or methylation in BRCA1/2.

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates AG014699's effectiveness in tumors with mutated BRCA genes, suggesting therapeutic implications.

This research aims to evaluate the antitumor activity of the PARP inhibitor AG014699 in human cancer cells with mutations or methylation in BRCA1/2.
Conducted in vitro and in vivo investigations using nine human cell lines with varying BRCA1/2 status.
Assessed cytotoxicity, DNA damage, and homologous recombination repair (HRR) function.
Evaluated the growth of xenograft tumors in mouse models to determine AG014699's antitumor activity.
AG014699 was cytotoxic to cells with mutated BRCA1/2 and epigenetically silenced BRCA1 but not to non-mutated cells.
Induced DNA double-strand breaks across all cell lines tested, with HRR only in cells with functional BRCA1/2.
Combination treatment with AG014699 and carboplatin was more effective than either drug alone.

Drew et al. (2010) studied this question.

View Full Paper

Ask AI

Bookmark